These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304 [TBL] [Abstract][Full Text] [Related]
35. Bladder cancer and BCG response prediction: what we must know? Cai T; Malossini G Cancer; 2011 Feb; 117(4):872; author reply 872-3. PubMed ID: 20922798 [No Abstract] [Full Text] [Related]
36. Primary neuroendocrine carcinoma of the urethra. Parekh DJ; Jung C; Roberts R; Shappell S; Smith JA Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475683 [TBL] [Abstract][Full Text] [Related]
37. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
38. Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Brandau S Eur Urol; 2008 Sep; 54(3):629-30. PubMed ID: 18222602 [No Abstract] [Full Text] [Related]